Pneumococcal vaccines: history, current status, and future directions.
about
Pneumococcal conjugate vaccines for preventing vaccine-type invasive pneumococcal disease and pneumonia with consolidation on x-ray in children under two years of ageIntranasal vaccination with pneumococcal surface protein A and interleukin-12 augments antibody-mediated opsonization and protective immunity against Streptococcus pneumoniae infection.Molecular epidemiology of pneumococcal colonization in response to pneumococcal conjugate vaccination in children with recurrent acute otitis mediaUse of HL-60 cell line to measure opsonic capacity of pneumococcal antibodiesPppA, a surface-exposed protein of Streptococcus pneumoniae, elicits cross-reactive antibodies that reduce colonization in a murine intranasal immunization and challenge model.Intranasal immunization of mice with a mixture of the pneumococcal proteins PsaA and PspA is highly protective against nasopharyngeal carriage of Streptococcus pneumoniae.Synthetic polysaccharide type 3-related di-, tri-, and tetrasaccharide-CRM(197) conjugates induce protection against Streptococcus pneumoniae type 3 in mice.Pneumococcal virulence factors: structure and functionCross-protective immunity of mice induced by oral immunization with pneumococcal surface adhesin a encapsulated in microspheres.Pneumococcal resistance: the treatment challenge.Pneumococcal vaccination and revaccination of older adults.Comparative immune responses of patients with chronic pulmonary diseases during the 2-year period after pneumococcal vaccination.Immune Responses to pneumococcal vaccines in children and adults: Rationale for age-specific vaccination.Alterations in marginal zone macrophages and marginal zone B cells in old miceHyposplenism: a comprehensive review. Part II: clinical manifestations, diagnosis, and management.Bacterial meningitis: a review of effective pharmacotherapy.Multilaboratory evaluation of a viability assay for measurement of opsonophagocytic antibodies specific to the capsular polysaccharides of Streptococcus pneumoniaeHigher risk for incident heart failure and cardiovascular mortality among community-dwelling octogenarians without pneumococcal vaccination.Immunoblot method to detect Streptococcus pneumoniae and identify multiple serotypes from nasopharyngeal secretions.Streptococcus pneumoniae surface protein PcpA elicits protection against lung infection and fatal sepsisDrug-resistant genes and serotypes of pneumococcal strains of community-acquired pneumonia among adults in Japan.Recombinant PhpA protein, a unique histidine motif-containing protein from Streptococcus pneumoniae, protects mice against intranasal pneumococcal challenge.Intranasal immunization with autolysin (LytA) in mice model induced protection against five prevalent Streptococcus pneumoniae serotypes in China.PspA protects Streptococcus pneumoniae from killing by apolactoferrin, and antibody to PspA enhances killing of pneumococci by apolactoferrin [corrected].Pneumococcal surface protein A is expressed in vivo, and antibodies to PspA are effective for therapy in a murine model of pneumococcal sepsisResistant shock in a haemodialysed patient--why?Streptococcus pneumoniae and chronic endobronchial infections in childhood.
P2860
Q24245934-DC7FE1F0-5D96-4412-B53D-E14AC56A4085Q33552360-7E0C8A56-0BFE-433B-9F79-E0C06876CA5DQ33593187-C06CDB3E-FFA4-428F-8EDC-DEFC840A5B98Q33593722-D76373BA-9D3C-4510-ADE4-025F7CCA7C31Q33795071-2D7894F9-6509-4068-B0C7-AFFE1B4262CAQ34003306-50A88B6B-7A7E-4AFE-8320-6E92B3B2E0A3Q34008431-DD049554-12BF-4BED-AD52-360782AF5B92Q34010335-DE00925C-1D4F-4A4B-92C6-302DAFE87F94Q34120517-C2D19C68-D0B0-4A34-867A-250B2159248AQ34219099-E750AFE7-6FBB-4F89-B3C3-E9177A38E1FCQ34926870-52C55002-B410-4A1B-8E34-EF20EF4A0368Q35636112-3288D785-AC13-4BDB-93B2-5FD46BE84646Q35874108-ED3406B8-6B5B-4FEA-A4CB-D906D534F6D6Q36168169-B6D10CA4-F823-4896-A350-F5C6FC2C22CBQ36799619-257340D1-A3A9-43F8-9A55-3468B221CD45Q36895844-7FE72B54-66D6-4362-8E94-C53DC36FBD69Q37057886-3FBA04BA-BFD8-4B5E-BA2B-1B5F6B32BAB5Q37248663-68191C6D-5550-4978-9CAC-DE5AE3D17FA5Q37419564-33C6E6C4-6F8F-48B0-906C-279B9DA06F1EQ39023214-19D09537-A4F4-45D7-990B-7989E22CC3CDQ39318842-B6AB3BD8-72E6-4CC2-89F3-E65825A0C10BQ39520643-F9F7CC77-B2AD-4D83-AC90-B1E62309667CQ39620052-1371700F-03A9-40F7-9DC9-05D8FDAF9D78Q40014811-972C41FD-2356-4EDC-957A-013B0B5D5553Q40403830-25BCA6FE-766F-4ACD-B692-7AF68D8E801CQ44044675-D165DC65-A463-4018-8E31-CFFB28034D59Q47770066-5B6D3ED7-01C3-4862-83A9-53D2FE99A295
P2860
Pneumococcal vaccines: history, current status, and future directions.
description
1999 nî lūn-bûn
@nan
1999 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Pneumococcal vaccines: history, current status, and future directions.
@ast
Pneumococcal vaccines: history, current status, and future directions.
@en
type
label
Pneumococcal vaccines: history, current status, and future directions.
@ast
Pneumococcal vaccines: history, current status, and future directions.
@en
prefLabel
Pneumococcal vaccines: history, current status, and future directions.
@ast
Pneumococcal vaccines: history, current status, and future directions.
@en
P2093
P1476
Pneumococcal vaccines: history, current status, and future directions.
@en
P2093
P304
P356
10.1016/S0002-9343(99)00105-9
P407
P577
1999-07-01T00:00:00Z